IPSC vs LCTX
IPSC: Century Therapeutics is an innovative biotechnology firm developing off-the-shelf, gene-edited iPSC-derived cell therapies to cure cancer and autoimmune diseases. LCTX: Lineage Cell Therapeutics develops allogeneic cell therapy treatments for serious human diseases through its AlloSCOPE™ manufacturing platform and partnerships with major pharmaceutical companies.
Side-by-side fundamentals
| Metric | IPSC | LCTX | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $2.15 | $1.11 | |
| Market cap as of 2026-07-23 | $388M | $278M | |
| PEG as of 2026-07-23 | -0.01 | -0.02 | LCTX lower |
| Net margin as of 2026-07-23 | -18.9% | -431.2% | IPSC higher |
| Gross margin as of 2026-07-23 | n/a | +94.1% | |
| Operating margin as of 2026-07-23 | -28.6% | -256.5% | IPSC higher |
| ROE as of 2026-07-23 | -53.2% | -151.3% | IPSC higher |
| ROA as of 2026-07-23 | -39.9% | -63.3% | IPSC higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.00 | IPSC lower |
| Revenue growth (YoY) as of 2026-07-23 | +175.9% | -37.1% | IPSC higher |
| Revenue CAGR (3y) SEC XBRL | +175.9% | -0.3% | IPSC higher |
| Beta as of 2026-07-23 | 1.58 | 1.51 | |
| 1-year return as of 2026-07-22 close | +289.6% | +16.8% | IPSC higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.